eXoZymes Inc. Announces Closing of $6 Million Public Offering

eXoZymes (NASDAQ:EXOZ) closed a public offering of 330,575 units, including 34,440 from partial over-allotment exercise.

Rhea-AI Summary

eXoZymes (NASDAQ:EXOZ) closed a public offering of 330,575 units, including 34,440 from partial over-allotment exercise. Each unit includes two common shares and one warrant. The offering priced shares at $8.99 and warrants at $0.02, for gross proceeds of about $5.95 million.

Warrants become exercisable in one year at $11.24 per share, last five years, and are unlisted. According to eXoZymes, net proceeds will fund NCT development, additional products, R&D, working capital, and general corporate purposes.

Positive

• Gross offering proceeds of approximately $5.95 million before expenses
• Financing supports NCT development and additional product opportunities
• Funds allocated to research and development and working capital

Negative

• Issuance of new shares and warrants may dilute existing shareholders
• Warrant exercise price may reset as low as $0.001
• Unlisted warrants could create overhang without active trading market

Argus Jun 18 session

+23.70% close to close Open Argus

Details

News Market Reaction – EXOZ

On Jun 18, the first trading day after this news, EXOZ closed 23.70% above the previous close.

Data tracked by StockTitan Argus for the Jun 18 session.

Market Context

On Jun 18, the first trading day after this news, the stock closed 23.7% above the previous close. A...

Analysis

On Jun 18, the first trading day after this news, the stock closed 23.7% above the previous close. A strong positive reaction aligns with the company’s need to strengthen its balance sheet, as disclosed in prior filings, even though offerings often weigh on shares. The deal raised about $5.95 million and draws on a $50,000,000 S-3 shelf. Historically, the prior offering on Jun 8, 2026 saw a -3.64% move, so a large gain would mark a departure from that pattern.

Key Figures

Gross proceeds: $5.95 million Units sold: 330,575 units Public offering price: $8.99 per share +5 more

Gross proceeds

$5.95 million

Gross proceeds from June 17, 2026 public offering before fees

Units sold

330,575 units

Common stock and warrant units in the June 17, 2026 offering

Public offering price

$8.99 per share

Common stock price in the June 17, 2026 offering

Warrant price

$0.02 per warrant

Public offering price per warrant in the unit offering

Warrant exercise price

$11.24 per share

Exercise price, warrants exercisable one year after issuance

Warrant reset price

$0.001 per share

Potential reset if future equity is sold below $8.99 before Jun 5, 2027

Shelf registration size

$50,000,000

Maximum securities registered under Form S-3 shelf filed Jan 16, 2026

Warrant term

5 years

Warrants expire on the five-year anniversary of issuance

Previous Offering Reports

1 past event · Latest: Jun 08

Same Type 1 event

1. Jun 08

   Equity offering pricing

   24h Move

   -3.6%

   Priced unit offering of stock and warrants for about $5.33M gross.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

underwritten public offering, warrant, over-allotment option, shelf registration statement, +2 more

6 terms

underwritten public offering financial

"announced the closing of its previously announced underwritten public offering of common stock and warrants"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

warrant financial

"each unit consisting of two shares of common stock and one warrant to purchase one additional share"

A warrant is a time-limited financial contract that gives its holder the right to buy a company's shares at a set price before a specified date, like a coupon that lets you purchase stock at a fixed discount for a limited time. It matters to investors because warrants offer leveraged exposure to a stock’s upside and can dilute existing shareholders if exercised, so they affect potential gains and the company’s outstanding share count.

over-allotment option financial

"including 34,440 units sold in partial exercise of over-allotment option"

An over-allotment option is a special agreement that allows underwriters to sell more shares than initially planned if demand is high. Think of it like a retailer offering extra units of a popular product to meet additional customer interest. This option helps ensure the full sale is completed and can also give investors extra shares if they want more.

shelf registration statement regulatory

"offered pursuant to a shelf registration statement on Form S-3 (File No. 333-292781)"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form s-3 regulatory

"shelf registration statement on Form S-3 (File No. 333-292781)"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

prospectus supplement regulatory

"A final prospectus supplement and accompanying prospectus describing the terms of the offering was filed"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LOS ANGELES, CA / ACCESS Newswire / June 17, 2026 / eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes" or "Company"), a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines, today announced the closing of its previously announced underwritten public offering of common stock and warrants.

The offering consisted of 330,575 units, including 34,440 units sold in partial exercise of over-allotment option, each unit consisting of two shares of common stock and one warrant to purchase one additional share of common stock. The public offering price per share was $8.99 and per warrant was $0.02 resulting in gross proceeds of approximately $5.95 million before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.

The warrants become exercisable one year from the date of issuance at an exercise price of $11.24 per share and expire on the five-year anniversary of the issuance date. The warrants are not listed on any national securities exchange or other trading market and may be redeemed by the Company upon occurrence of certain conditions. The warrant exercise price may be reset to $0.001 in the event the Company sells in a public or private offering before June 5, 2027, additional shares of common stock, or securities convertible into common stock, at a per share price (or equivalent) of less than $8.99.

The Company intends to use net proceeds from the offering to support development and commercialization activities related to N-trans-caffeoyltyramine ("NCT"), advance additional product opportunities, fund research and development activities, and for working capital and other general corporate purposes.

MDB Capital acted as sole book-running manager for the offering. The securities described above were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-292781), which was declared effective by the U.S. Securities and Exchange Commission ("SEC") on January 23, 2026. A final prospectus supplement and accompanying prospectus describing the terms of the offering was filed with the SEC on June 8, 2026 and are available on the SEC's website at www.sec.gov.

About eXoZymes
Founded in 2019, the company has developed a biomanufacturing platform that - as a historic first - offers the tools and insights to design, engineer, control and optimize nature's own natural processes to produce highly valuable natural products, via a commercially scalable, sustainable, and abundant alternative: exozymes.

Exozymes are advanced enzymes enhanced through bioengineering and AI to thrive in a bioreactor without using living cells. Exozymes can replace toxic petrochemical processes and inefficient biochemical extraction with sustainable and scalable biosolutions that transform abundant feedstock into valuable nutraceuticals and novel medicines.

By freeing enzyme-driven chemical reactions from cellular constraints, exozyme biosolutions remove the scaling bottleneck that has impeded synthetic biology's commercial success, paving the way for exozymes to lead the next generation of biomanufacturing innovation. eXoZymes Inc. introduced "exozymes" as an open scientific concept rather than as a trademark. By offering this new nomenclature for wide industry adoption, the company aims to pioneer this next generation of cell-free biomanufacturing and establish itself as the market leader. Learn more at exozymes.com.

eXoZymes Safe Harbor
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which are based on certain assumptions and describe the company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely," "potential," or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Actual results could differ materially for a variety of reasons. You should carefully consider the risks and uncertainties described in the "Risk Factors" section of eXoZymes' quarterly reports on Form 10-Q, annual reports on Form 10-K, and other documents filed by eXoZymes from time to time by the company with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in the final prospectus related to the public offering that was filed with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and eXoZymes assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. eXoZymes does not give any assurance that it will achieve its expectations.

eXoZymes contact
Lasse Görlitz, VP of Comms & IR
(858) 319-7135
press@exozymes.com

https://www.linkedin.com/company/exozymes
https://x.com/exozymes
https://www.youtube.com/@exozymes

SOURCE: eXoZymes

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did eXoZymes (NASDAQ:EXOZ) announce on June 17, 2026 about its public offering?

eXoZymes announced the closing of an underwritten public offering raising about $5.95 million in gross proceeds. According to eXoZymes, the deal included 330,575 units of common stock and warrants, including 34,440 units from a partial over-allotment exercise.

What are the pricing details of the June 2026 EXOZ stock and warrant offering?

The offering priced common shares at $8.99 and warrants at $0.02 each. According to eXoZymes, each unit contained two shares and one warrant, resulting in total gross proceeds of approximately $5.95 million before underwriting discounts and expenses.

What are the warrant terms in eXoZymes (EXOZ) June 2026 public offering?

The warrants become exercisable one year after issuance at an exercise price of $11.24 and expire after five years. According to eXoZymes, they are unlisted, redeemable upon certain conditions, and their exercise price may reset to $0.001 under specific future financing terms.

How will eXoZymes (EXOZ) use the proceeds from its June 2026 offering?

eXoZymes plans to use net proceeds to support development and commercialization of N-trans-caffeoyltyramine (NCT). According to eXoZymes, funds will also advance additional product opportunities, support research and development, and provide working capital and other general corporate purposes.

Does the June 2026 EXOZ equity offering affect existing shareholders through dilution?

Issuing new shares and warrants can dilute existing shareholders’ ownership percentage over time. According to eXoZymes, the offering included 330,575 units, each with two common shares and one warrant, which may increase the share count if warrants are exercised.

Who managed the June 2026 eXoZymes (EXOZ) public offering and under what registration?

MDB Capital acted as sole book-running manager for the public offering. According to eXoZymes, the securities were issued under an effective shelf registration statement on Form S-3, file number 333-292781, declared effective on January 23, 2026.